Evidence map›Paper›PMID 39319998›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

Christopher Lloyd, Per-Ola Freskgård, Philip Newton, David Lowne, Adrian Nickson, Anna Bogstedt, Susanna Eketjäll, Kina Höglund, Susanne Gustavsson, Fraser Welsh and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Christopher LloydBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Per-Ola FreskgårdBioArctic AB, Stockholm, Sweden.
Philip NewtonBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
David LowneBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Adrian NicksonBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Anna BogstedtBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Susanna EketjällBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Kina HöglundCenter for Medical Genomics, Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Göteborg, Sweden.
Susanne GustavssonBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Fraser WelshBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Tharani ChessellBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Mary McFarlaneBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Ratan V BhatBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Richard TurnerBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Michael S PerkintonBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Zulma Santisteban ValenciaBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Eva LindqvistBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Michael PomfretBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Amanda D DudleyBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Tristan J VaughanBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Maria T GrovesBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Fanni NatanegaraLilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Yingdong FengLilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
John R SimsLilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Nicholas Kyle ProctorLilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Jeffrey L DageLilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Craig SheringBioPharmaceuticals R&D, AstraZeneca, Cambridge, Massachusetts, USA.
Keith TanBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Thor OstenfeldBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Andy BillintonBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Iain P ChessellBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSmall molecules and antibodies are being developed to lower amyloid beta (Aβ) peptides.

methodsWe describe MEDI1814, a fully human high-affinity monoclonal antibody selective for Aβ

resultsMEDI1814 reduces free Aβ DISCUSSION: MEDI1814 offers a differentiated approach to impacting Aβ in AD via selective reduction of free Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedMacaca fascicularisPeptide FragmentsAgedAged, 80 and overAnimalsDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedRatsAmyloid beta-Peptidesamyloid beta-protein (1-42)Antibodies, Monoclonal, HumanizedPeptide Fragmentsamyloid beta 42drug developmentpharmacodynamicspharmacokineticspreclinicalsafetytolerability

Identifiers

PMID39319998
PMCPMC11567870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.